CN103687590A - 用于靶向给药的多孔纳米颗粒支撑脂双层（原始细胞）及其使用方法 - Google Patents

用于靶向给药的多孔纳米颗粒支撑脂双层（原始细胞）及其使用方法 Download PDF

Info

Publication number
CN103687590A
CN103687590A CN201280031496.8A CN201280031496A CN103687590A CN 103687590 A CN103687590 A CN 103687590A CN 201280031496 A CN201280031496 A CN 201280031496A CN 103687590 A CN103687590 A CN 103687590A
Authority
CN
China
Prior art keywords
cell
protocell
inhibitors
cancer
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280031496.8A
Other languages
English (en)
Chinese (zh)
Inventor
J·C·布林克
E·C·卡恩斯
C·E·艾什莉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Technology and Engineering Solutions of Sandia LLC
UNM Rainforest Innovations
Original Assignee
STC UNM
Sandia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STC UNM, Sandia Corp filed Critical STC UNM
Publication of CN103687590A publication Critical patent/CN103687590A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
CN201280031496.8A 2011-04-28 2012-04-27 用于靶向给药的多孔纳米颗粒支撑脂双层（原始细胞）及其使用方法 Pending CN103687590A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161479847P 2011-04-28 2011-04-28
US61/479,847 2011-04-28
PCT/US2012/035529 WO2012149376A2 (en) 2011-04-28 2012-04-27 Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same

Publications (1)

Publication Number Publication Date
CN103687590A true CN103687590A (zh) 2014-03-26

Family

ID=47073093

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280031496.8A Pending CN103687590A (zh) 2011-04-28 2012-04-27 用于靶向给药的多孔纳米颗粒支撑脂双层（原始细胞）及其使用方法

Country Status (7)

Country Link
US (3) US9579283B2 (enExample)
EP (1) EP2701686A4 (enExample)
JP (1) JP2014512409A (enExample)
CN (1) CN103687590A (enExample)
AU (1) AU2012249474A1 (enExample)
CA (1) CA2834365A1 (enExample)
WO (1) WO2012149376A2 (enExample)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104023711A (zh) * 2011-10-14 2014-09-03 Stc.Unm公司 用于靶向递送(包括负载物的透皮递送)的多孔纳米颗粒支撑的脂质双层(原始细胞)及其方法
CN104667290A (zh) * 2014-10-25 2015-06-03 中国科学技术大学 一种靶向肽修饰的金纳米颗粒及其制备方法和其作为四价铂前体药物载体的应用
CN105456198A (zh) * 2015-12-25 2016-04-06 正大天晴药业集团股份有限公司 一种荷载恩替卡韦介孔二氧化硅纳米粒及其制备方法
CN107920964A (zh) * 2015-07-09 2018-04-17 加利福尼亚大学董事会 融合脂质体包被的多孔硅纳米颗粒
CN108367076A (zh) * 2015-10-22 2018-08-03 德尔科技有限公司 水凝胶复合材料药性持久制剂
CN108938595A (zh) * 2018-07-15 2018-12-07 河南工业大学 一种共载siRNA与化疗药物的阳离子脂质-介孔硅复合纳米载体的制备方法
CN110120249A (zh) * 2019-05-23 2019-08-13 复旦大学 通过靶向调控动力学路径构造靶向构造目标结构的方法
CN111991558A (zh) * 2020-08-28 2020-11-27 安徽贝克生物制药有限公司 一种抗逆转录病毒药物组合物及其制备方法
CN112480212A (zh) * 2020-12-17 2021-03-12 中国药科大学 靶向肝细胞生长因子的高亲和肽及其应用
CN113616618A (zh) * 2017-09-22 2021-11-09 杭州景杰生物科技有限公司 利用微混合和卡培他滨两亲性特性的卡培他滨的聚合物-脂质混杂纳米颗粒
CN114949250A (zh) * 2016-04-14 2022-08-30 斯宾纳克生物科学公司 用于递送治疗剂的组合物、药物组合物、制备方法以及用途
US20230321032A1 (en) * 2022-04-06 2023-10-12 University Of Kentucky Research Foundation Functionalized mesoporous silica nanoparticles for treatment of periodontal disease

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5660561B2 (ja) * 2006-09-28 2015-01-28 ハダシット メディカルリサーチサービセス アンド ディベロップメント リミテッド ジョイント部の潤滑に関するグリセロリン脂質の使用
US8992984B1 (en) 2009-10-21 2015-03-31 Stc.Unm Protocells and their use for targeted delivery of multicomponent cargos to cancer cells
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
JP2014512409A (ja) * 2011-04-28 2014-05-22 エスティーシー． ユーエヌエム 標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその使用方法
EP3412282B1 (en) * 2011-06-02 2024-10-09 The Regents of the University of California Membrane encapsulated nanoparticles and method of use
AU2012284147A1 (en) 2011-07-19 2014-02-27 Stc. Unm Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013103614A1 (en) * 2011-12-30 2013-07-11 Stc.Unm Crlf-2 binding peptides, protocells and viral-like particles useful in the treatment of cancer, including acute lymphoblastic leukemia (all)
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9273305B1 (en) 2012-04-25 2016-03-01 Sandia Corporation Cell-based composite materials with programmed structures and functions
CN113842362A (zh) 2012-11-14 2021-12-28 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
EP2943565B1 (en) 2013-01-14 2018-03-28 Fred Hutchinson Cancer Research Center Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
EP2964201B1 (en) * 2013-03-05 2024-02-14 The Regents of the University of California Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
US20140271815A1 (en) * 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
US9603799B2 (en) 2013-03-15 2017-03-28 Htd Biosystems Inc. Liposomal vaccine adjuvants and methods of making and using same
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2981249A4 (en) * 2013-04-02 2016-11-23 Stc Unm MESOPOROUS ALAN NANOPARTICLES AS A UNIVERSAL PLATFORM FOR ADSORPTION, PRESENTATION, AND ADMINISTRATION OF ANTIGENS
CN103989631A (zh) * 2013-04-15 2014-08-20 中国人民解放军第二军医大学 萝卜硫素制剂及其制备方法和应用
CN103990130A (zh) * 2013-06-24 2014-08-20 中国人民解放军第二军医大学 介孔二氧化硅纳米制剂及其制备方法和应用
US10272137B2 (en) 2013-06-27 2019-04-30 The Board Of Regents Of The University Of Texas System Compositions and methods relating to myomaker-induced muscle cell fusion
WO2015042268A1 (en) * 2013-09-18 2015-03-26 Stc.Unm Core and surface modification of mesoporous silica nanoparticles to achieve cell specific targeting in vivo
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
PT3981437T (pt) 2014-04-23 2025-01-15 Modernatx Inc Vacinas de ácidos nucleicos
CN115607688A (zh) 2014-07-22 2023-01-17 雷莫内克斯生物制药有限公司 用于递送生物活性物质或蛋白质的组合物及其用途
WO2016054225A1 (en) * 2014-09-30 2016-04-07 Stc.Unm Plasmid delivery in the treatment of cancer and other disease states
WO2016205515A1 (en) * 2015-06-17 2016-12-22 The Curators Of The University Of Missouri GOLD NANOROD BASED DIAGNOSTIC AGENT FOR DETECTION AND QUANTIFICATION OF c-MET (HGF) RECEPTORS
LU92783B1 (en) * 2015-07-22 2017-01-31 Luxembourg Inst Of Science And Tech (List) Highly aminated self-assembling fuctionalized Mesoporous Silicia Nanoparticles and methods of synthesis
LU92784B1 (en) * 2015-07-22 2017-01-31 Luxembourg Inst Of Science And Tech (List) Negatively charged self-assembling supported lipid bilayer on mesoporous silica nanoparticles, method of synthesis and use as a nanovector
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
JP2017038539A (ja) * 2015-08-18 2017-02-23 日本電信電話株式会社 脂質二分子膜基板
US20190262469A1 (en) * 2015-09-04 2019-08-29 C. Jeffrey Brinker Protocells to treat microbial infection and for synergistic delivery
US20180344641A1 (en) * 2015-09-04 2018-12-06 C. Jeffrey Brinker Mesoporous silica nanoparticles and supported lipid bi-layer nanoparticles for biomedical applications
SMT202200178T1 (it) 2015-09-17 2022-05-12 Modernatx Inc Composti e composizioni per il rilascio intracellulare di agenti terapeutici
US10016422B2 (en) * 2015-09-30 2018-07-10 Oregon State University Nanocarrier drug delivery platform
PL3394030T3 (pl) 2015-12-22 2022-04-11 Modernatx, Inc. Związki i kompozycje do wewnątrzkomórkowego dostarczania środków
WO2017117275A1 (en) * 2015-12-31 2017-07-06 City Of Hope Silica nanoparticle with platinum anti-cancer agent
WO2017120504A1 (en) * 2016-01-08 2017-07-13 Durfee Paul N Osteotropic nanoparticles for prevention or treatment of bone metastases
EP3399966B1 (en) 2016-01-08 2023-03-29 The Regents of the University of California Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
EP3429630A1 (en) * 2016-03-16 2019-01-23 Merrimack Pharmaceuticals, Inc. Nanoliposomal targeting of ephrin receptor a2 (epha2) and related diagnosticss
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
US10663450B2 (en) * 2016-06-15 2020-05-26 The University Of Chicago Amorphous, porous silicon materials and related methods
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP3558327A4 (en) * 2016-12-21 2020-12-09 Fred Hutchinson Cancer Research Center SCAFFOLDING TO TREAT SOLID TUMOR CELLS AND EXHAUST VARIANTS
US10874768B2 (en) * 2017-01-20 2020-12-29 Covidien Lp Drug eluting medical device
MX388358B (es) 2017-02-06 2025-03-19 Lemonex Inc Portador de sustancia fisiologicamente activa.
US11344629B2 (en) 2017-03-01 2022-05-31 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
AU2018234814B2 (en) 2017-03-15 2022-06-30 Modernatx, Inc. Crystal forms of amino lipids
AU2018234828A1 (en) 2017-03-15 2019-09-19 Modernatx, Inc. Lipid nanoparticle formulation
LT3596041T (lt) 2017-03-15 2023-01-25 Modernatx, Inc. Terapinių medžiagų, skirtų intraląsteliniam tiekimui, junginys ir sudėtys
WO2018187287A1 (en) * 2017-04-03 2018-10-11 Charles Jeffrey Brinker Porous nanoparticle-supported lipid bilayer delivery of transcriptional gene modulators
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
BR112019023323A2 (pt) * 2017-05-08 2020-07-21 Flagship Pioneering Innovations V, Inc. composições para facilitar a fusão de membrana e usos das mesmas
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
US11007516B1 (en) 2017-06-19 2021-05-18 National Technology & Engineering Solutions Of Sandia, Llc Tunable metal-organic framework compositions and methods thereof
CN110996911B (zh) * 2017-06-26 2023-01-17 福多兹制药公司 阿瑞匹坦的纳米微脂囊配制品及其方法和应用
AU2018308332B2 (en) * 2017-07-25 2021-11-18 Lemonex Inc. Composition for delivering physiologically active ingredients into blood vessel
CN111315359A (zh) 2017-08-31 2020-06-19 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
KR102152348B1 (ko) 2017-09-05 2020-09-08 주식회사 레모넥스 세포 운명 조절용 조성물
US10933027B1 (en) 2017-09-25 2021-03-02 National Technology & Engineering Solutions Of Sandia, Llc Expanded pore particles and delivery methods thereof
EP3735250A4 (en) 2018-01-01 2022-04-13 The Regents Of The University Of California INDUSTRIAL-SCALE SYNTHESIS OF SILICASOMES-TYPE NANOSUPPORTS
US20200405650A1 (en) * 2018-02-28 2020-12-31 Achraf Noureddine Starry mesoporous silica nanoparticles and supported lipid bi-layer nanoparticles
CA3099267A1 (en) 2018-05-08 2019-11-14 Yale University Protein capture membrane and method of use thereof
US11045554B1 (en) * 2018-06-22 2021-06-29 National Technology & Engineering Solutions Of Sandia, Llc Lipid-coated particles for treating viral infections
KR20210043574A (ko) 2018-07-09 2021-04-21 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 푸소좀 조성물 및 이의 용도
CA3113436A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020068798A1 (en) 2018-09-24 2020-04-02 Guo Jimin Living mammalian cells modified with functional modular nanoparticles
CN113631718A (zh) 2018-11-14 2021-11-09 旗舰先锋创新V股份有限公司 用于特定隔室货物递送的组合物和方法
WO2020102485A1 (en) * 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
US12208164B2 (en) 2019-02-28 2025-01-28 Unm Rainforest Innovations Modular metal-organic polyhedra superassembly compositions
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
BR112022004759A2 (pt) 2019-09-19 2022-06-21 Modernatx Inc Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos
CN111529505B (zh) * 2020-03-25 2023-04-11 西安组织工程与再生医学研究所 功能性嵌合凋亡小体及其制备方法和应用
CN111529504B (zh) * 2020-03-25 2023-01-10 西安组织工程与再生医学研究所 功能性嵌合凋亡小体及其制备方法和应用
US11433121B1 (en) 2020-04-03 2022-09-06 National Technology & Engineering Solutions Of Sandia, Llc Lipid composition for the delivery of therapeutic cargos
CN111588704B (zh) * 2020-07-01 2023-04-11 西安组织工程与再生医学研究所 靶向响应性释放系统及其制备方法和应用
CN112168977A (zh) * 2020-10-27 2021-01-05 西南大学 转铁蛋白修饰的二氧化硅荷载白藜芦醇及制备方法和应用
CA3216353A1 (en) 2021-04-08 2022-10-13 Sana Biotechnology, Inc. Cd8-specific antibody constructs and compositions thereof
US12194458B2 (en) * 2022-08-16 2025-01-14 Nicole Shamayev Device and method of portable drug testing
US12098200B1 (en) 2022-10-12 2024-09-24 National Technology & Engineering Solutions Of Sandia, Llc Brain-targeting single domain antibodies and purification methods
WO2024182425A1 (en) * 2023-02-27 2024-09-06 Noureddine Achraf Compositions and methods for treating metabolic diseases/disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101658533A (zh) * 2008-08-29 2010-03-03 首都医科大学宣武医院 抗肿瘤药物的干细胞递送

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5277913A (en) 1991-09-09 1994-01-11 Thompson David H Liposomal delivery system with photoactivatable triggered release
US5820879A (en) 1993-02-12 1998-10-13 Access Pharmaceuticals, Inc. Method of delivering a lipid-coated condensed-phase microparticle composition
EP0692972B2 (en) 1993-04-02 2012-03-21 AntiCancer, Inc. Method for delivering beneficial compositions to hair follicles
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
ATE419273T1 (de) * 1998-11-13 2009-01-15 Cyclacel Ltd Translokationsvektoren abgeleitet von der antennapedia homeodomain helix 3
CA2371728C (en) 1999-06-11 2009-06-02 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
GB0104259D0 (en) * 2001-02-21 2001-04-11 Smithkline Beecham Biolog Novel compounds
WO2003016040A1 (en) 2001-04-16 2003-02-27 The Regents Of The University Of California Membrane mimetic architectures on nanoporous materials
IL162183A0 (en) 2001-12-21 2005-11-20 Celator Technologies Inc Polymer-lipid delivery vehicles and methods for the preparation thereof
US20040005352A1 (en) 2002-04-16 2004-01-08 Lopez Gabriel P. Biologically functionalized porous microspheres
US20040101822A1 (en) 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US7563451B2 (en) 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
BRPI0607321A2 (pt) 2005-02-14 2009-09-01 Australian Nuclear Science Tech Org nanopartìculas em camadas
US8465983B1 (en) 2005-08-19 2013-06-18 Gabriel P. Lopez Detection and delivery systems utilizing supported lipid bilayers
BRPI0618488A2 (pt) 2005-11-10 2011-08-30 Receptor Biologix Inc proteìnas de fusão de ìntron de fator de crescimento de hepatócito
US20080160313A1 (en) * 2006-04-26 2008-07-03 Gabriel Lopez Lipid bilayers on nanotextured solid surfaces
WO2007140618A1 (en) 2006-06-09 2007-12-13 Protox Therapeutics Incorporated Modified protein toxins targeting cytokine -receptor bearing cells and use thereof for treating disease
US9803189B2 (en) 2006-08-23 2017-10-31 Stc.Unm Virus-like platform for rapid vaccine discovery
EP2099496A2 (en) 2006-12-08 2009-09-16 Massachusetts Institute of Technology Delivery of nanoparticles and/or agents to cells
US20080279764A1 (en) 2007-03-09 2008-11-13 Anthony Manganaro Method and composition for treating cancer
US9993437B2 (en) 2007-12-06 2018-06-12 The Regents Of The University Of California Mesoporous silica nanoparticles for biomedical applications
WO2009091531A2 (en) 2008-01-16 2009-07-23 The General Hospital Corporation Uniform-sized, multi-drug carrying and photosensitive liposomes for advance drug delivery
CN102036652B (zh) 2008-04-25 2016-04-13 西北大学 适于螯合胆甾醇的纳米结构
WO2010048572A1 (en) 2008-10-23 2010-04-29 Cornell University A novel anti-viral method
US20110230372A1 (en) 2008-11-14 2011-09-22 Stc Unm Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and outcome prediction in pediatric b-precursor acute lymphoblastic leukemia
WO2010078569A2 (en) 2009-01-05 2010-07-08 Stc.Unm Porous nanoparticle supported lipid bilayer nanostructures
US8992984B1 (en) 2009-10-21 2015-03-31 Stc.Unm Protocells and their use for targeted delivery of multicomponent cargos to cancer cells
US20130017210A1 (en) 2010-03-17 2013-01-17 Stc.Unm Display of antibody fragments on virus-like particles of rna bacteriophages
US20110300186A1 (en) 2010-04-14 2011-12-08 Battelle Memorial Institute Functionalized Nano- and Micro-materials for Medical Therapies
JP2014512409A (ja) 2011-04-28 2014-05-22 エスティーシー． ユーエヌエム 標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその使用方法
AU2012284147A1 (en) 2011-07-19 2014-02-27 Stc. Unm Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
WO2013056132A2 (en) 2011-10-14 2013-04-18 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
WO2013103614A1 (en) 2011-12-30 2013-07-11 Stc.Unm Crlf-2 binding peptides, protocells and viral-like particles useful in the treatment of cancer, including acute lymphoblastic leukemia (all)
EP2981249A4 (en) 2013-04-02 2016-11-23 Stc Unm MESOPOROUS ALAN NANOPARTICLES AS A UNIVERSAL PLATFORM FOR ADSORPTION, PRESENTATION, AND ADMINISTRATION OF ANTIGENS
WO2014165608A1 (en) 2013-04-02 2014-10-09 Stc. Unm Antibiotic protocells and related pharmaceutical formulations and methods of treatment
US9855217B2 (en) 2013-09-18 2018-01-02 Stc. Unm Toroidal mesoporous silica nanoparticles (TMSNPs) and related protocells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101658533A (zh) * 2008-08-29 2010-03-03 首都医科大学宣武医院 抗肿瘤药物的干细胞递送

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARLEE E. ASHLEY ET.AL: "The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers", 《NATURE MATERIALS》, vol. 10, 17 April 2011 (2011-04-17), pages 389 - 397, XP055132474, DOI: 10.1038/nmat2992 *
JUEWEN LIU ET.AL: "Porous Nanoparticle Supported Lipid Bilayers (Protocells) as Delivery Vehicles", 《J AM CHEM SOC》, vol. 131, no. 4, 4 February 2009 (2009-02-04), pages 1354 - 1355, XP055029872, DOI: 10.1021/ja808018y *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104023711A (zh) * 2011-10-14 2014-09-03 Stc.Unm公司 用于靶向递送(包括负载物的透皮递送)的多孔纳米颗粒支撑的脂质双层(原始细胞)及其方法
CN104667290A (zh) * 2014-10-25 2015-06-03 中国科学技术大学 一种靶向肽修饰的金纳米颗粒及其制备方法和其作为四价铂前体药物载体的应用
CN107920964A (zh) * 2015-07-09 2018-04-17 加利福尼亚大学董事会 融合脂质体包被的多孔硅纳米颗粒
CN114533898B (zh) * 2015-07-09 2025-07-01 加利福尼亚大学董事会 融合脂质体包被的多孔硅纳米颗粒
US11406597B2 (en) 2015-07-09 2022-08-09 The Regents Of The University Of California Fusogenic liposome-coated porous silicon nanoparticles
CN114533898A (zh) * 2015-07-09 2022-05-27 加利福尼亚大学董事会 融合脂质体包被的多孔硅纳米颗粒
CN107920964B (zh) * 2015-07-09 2022-02-25 加利福尼亚大学董事会 融合脂质体包被的多孔硅纳米颗粒
CN108367076A (zh) * 2015-10-22 2018-08-03 德尔科技有限公司 水凝胶复合材料药性持久制剂
CN108367076B (zh) * 2015-10-22 2021-08-31 德尔科技有限公司 水凝胶复合材料药性持久制剂
CN105456198A (zh) * 2015-12-25 2016-04-06 正大天晴药业集团股份有限公司 一种荷载恩替卡韦介孔二氧化硅纳米粒及其制备方法
CN105456198B (zh) * 2015-12-25 2017-04-26 正大天晴药业集团股份有限公司 一种荷载恩替卡韦介孔二氧化硅纳米粒及其制备方法
CN114949250A (zh) * 2016-04-14 2022-08-30 斯宾纳克生物科学公司 用于递送治疗剂的组合物、药物组合物、制备方法以及用途
CN113616618A (zh) * 2017-09-22 2021-11-09 杭州景杰生物科技有限公司 利用微混合和卡培他滨两亲性特性的卡培他滨的聚合物-脂质混杂纳米颗粒
CN108938595B (zh) * 2018-07-15 2021-09-14 河南工业大学 一种共载siRNA与化疗药物的阳离子脂质-介孔硅复合纳米载体的制备方法
CN108938595A (zh) * 2018-07-15 2018-12-07 河南工业大学 一种共载siRNA与化疗药物的阳离子脂质-介孔硅复合纳米载体的制备方法
CN110120249A (zh) * 2019-05-23 2019-08-13 复旦大学 通过靶向调控动力学路径构造靶向构造目标结构的方法
CN111991558A (zh) * 2020-08-28 2020-11-27 安徽贝克生物制药有限公司 一种抗逆转录病毒药物组合物及其制备方法
CN112480212A (zh) * 2020-12-17 2021-03-12 中国药科大学 靶向肝细胞生长因子的高亲和肽及其应用
US20230321032A1 (en) * 2022-04-06 2023-10-12 University Of Kentucky Research Foundation Functionalized mesoporous silica nanoparticles for treatment of periodontal disease

Also Published As

Publication number Publication date
US10022327B2 (en) 2018-07-17
EP2701686A2 (en) 2014-03-05
US20140079774A1 (en) 2014-03-20
US20190091150A1 (en) 2019-03-28
US20160106671A1 (en) 2016-04-21
EP2701686A4 (en) 2014-11-05
CA2834365A1 (en) 2012-11-01
WO2012149376A3 (en) 2013-01-17
US9579283B2 (en) 2017-02-28
AU2012249474A1 (en) 2013-11-07
WO2012149376A2 (en) 2012-11-01
JP2014512409A (ja) 2014-05-22

Similar Documents

Publication Publication Date Title
CN103687590A (zh) 用于靶向给药的多孔纳米颗粒支撑脂双层（原始细胞）及其使用方法
US20150272885A1 (en) Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
Pearce et al. Peptide targeted lipid nanoparticles for anticancer drug delivery
US20200197536A1 (en) Porous nanoparticle-supported lipid bilayer delivery of transcriptional gene modulators
US20180110831A1 (en) Cd 47 containing porous nanoparticle supported lipid bilayers (protocells) field of the invention
US20200375912A1 (en) Liposomal coated nanoparticles for immunotherapy applications
Houdaihed et al. Dual-targeted delivery of nanoparticles encapsulating paclitaxel and everolimus: a novel strategy to overcome breast cancer receptor heterogeneity.
CN108601746A (zh) 用于运载物递送的具有脂质双层包衣的中孔二氧化硅纳米颗粒
JP2014532071A5 (enExample)
Salzano et al. Transferrin-targeted nanoparticles containing zoledronic acid as a potential tool to inhibit glioblastoma growth
Bian et al. Awakening p53 in vivo by D-peptides-functionalized ultra-small nanoparticles: Overcoming biological barriers to D-peptide drug delivery
JP5436650B1 (ja) スーパーアパタイト超微細ナノ粒子
Li et al. Nanoparticle binding to urokinase receptor on cancer cell surface triggers nanoparticle disintegration and cargo release
Pan et al. Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer
Kim et al. Simultaneous regulation of apoptotic gene silencing and angiogenic gene expression for myocardial infarction therapy: Single-carrier delivery of SHP-1 siRNA and VEGF-expressing pDNA
EP3936121A1 (en) Self assembling molecules for targeted drug delivery
Yao et al. Nucleic acid nanomaterials-based therapy for osteoarthritis: Progress and prospects
US20230270882A1 (en) Peptide-nanoparticle conjugates
JP2003524624A (ja) 治療薬の組織への送達を高める方法及び組成物
CN111557926A (zh) 靶向性相变纳米药物系统及其制备方法与应用
Wang et al. Optimization of landscape phage fusion protein-modified polymeric PEG-PE micelles for improved breast cancer cell targeting
HK1190632A (en) Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
Wei et al. Therapeutic effect of hepatocellular carcinoma-targeting liposome delivery system loaded with c [RGDyk] modified combretastatin A-4 and adriamycin: a pharmacodynamics study
Duskey The development and biological evaluation of octreotide containing peptides for receptor mediated non-viral gene delivery
HK40065002A (en) Self assembling molecules for targeted drug delivery

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1190632

Country of ref document: HK

C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Brinch Jon Christian

Inventor after: CARNES ERIC C

Inventor after: ASHLEY CARLEE ERIN

Inventor after: C - L - Weierman

Inventor before: Brinch Jon Christian

Inventor before: CARNES ERIC C

Inventor before: ASHLEY CARLEE ERIN

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: JEFFREY C. BRINKER ERIC C. CARNES ASHLEY CARLEE ERIN TO: JEFFREY C. BRINKER ERIC C. CARNES ASHLEY CARLEE ERIN CHERYL L. WILLMAN

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140326

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1190632

Country of ref document: HK